Vertex Pharmaceuticals Incorporated Detailed Financials
Full historical quarterly statements
| Metric | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2.99B | 3.23B | 3.08B | 2.96B | 2.77B | 2.91B | 2.77B | 2.65B |
| Cost of Goods Sold | 392.8M | 466.0M | 414.8M | 407.5M | 363.0M | 423.4M | 392.6M | 371.9M |
| Gross Profit | 2.59B | 2.76B | 2.66B | 2.56B | 2.41B | 2.49B | 2.38B | 2.27B |
| R&D Expenses | 961.6M | 973.7M | 1.03B | 978.4M | 979.7M | 998.7M | 875.9M | 5.42B |
| Operating Expenses | 1.46B | 1.46B | 1.48B | 1.41B | 1.78B | 1.46B | 1.26B | 5.79B |
| Operating Income | 1.14B | 1.30B | 1.19B | 1.15B | 630.1M | 1.03B | 1.12B | -3.51B |
| Other Income / Gains | 114.8M | 30.6M | 112.6M | 131.9M | 100.3M | 110.5M | 107.8M | 123.5M |
| Net Income | 1.03B | 1.19B | 1.08B | 1.03B | 646.3M | 913.0M | 1.05B | -3.59B |
| EPS (Diluted) | 4.06 | 4.69 | 4.24 | 4.02 | 2.52 | 3.55 | 4.05 | -13.92 |
| Reported Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Gross Profit Ratio | 0.868 | 0.856 | 0.865 | 0.863 | 0.869 | 0.855 | 0.858 | 0.859 |
| General And Administrative Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling And Marketing Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling General And Administrative Expenses | 493.7M | 487.0M | 445.1M | 424.6M | 396.4M | 377.6M | 371.8M | 372.2M |
| Other Expenses | 700K | 0 | -1.9M | 3.1M | 401.0M | 86.3M | 15.3M | 500K |
| Cost And Expenses | 1.85B | 1.93B | 1.89B | 1.81B | 2.14B | 1.89B | 1.66B | 6.16B |
| Interest Income | 114.8M | 121.9M | 125.7M | 122.4M | 120.9M | 128.2M | 132.2M | 156.5M |
| Interest Expense | 0 | 3.3M | 3.3M | 3.7M | 3.0M | 2.8M | 7.5M | 9.9M |
| Depreciation And Amortization | 0 | 53.1M | 54.0M | 51.7M | 48.4M | 46.5M | 53.2M | 54.0M |
| Ebitda | 1.14B | 1.35B | 1.36B | 1.34B | 781.8M | 1.18B | 1.28B | -3.33B |
| Ebitdaratio | 0.381 | 0.419 | 0.441 | 0.451 | 0.282 | 0.407 | 0.464 | -1.258 |
| Operating Income Ratio | 0.381 | 0.403 | 0.386 | 0.388 | 0.227 | 0.352 | 0.403 | -1.329 |
| Income Before Tax | 1.25B | 1.33B | 1.30B | 1.28B | 730.4M | 1.14B | 1.22B | -3.39B |
| Income Before Tax Ratio | 0.419 | 0.412 | 0.422 | 0.433 | 0.264 | 0.39 | 0.442 | -1.282 |
| Income Tax Expense | 221.5M | 139.9M | 215.9M | 250.1M | 84.1M | 223.5M | 178.7M | 202.4M |
| Net Income Ratio | 0.345 | 0.369 | 0.352 | 0.348 | 0.233 | 0.314 | 0.377 | -1.358 |
| Epsdiluted | 4.02 | 4.65 | 4.20 | 3.99 | 2.49 | 3.50 | 4.01 | -13.92 |
| Weighted Average Shs Out | 254.1M | 253.9M | 255.6M | 256.7M | 256.9M | 257.5M | 258.0M | 258.1M |
| Weighted Average Shs Out Dil | 256.3M | 256.1M | 257.6M | 258.9M | 259.5M | 260.5M | 261.0M | 258.1M |